Brokerages Set Catalent, Inc. (NYSE:CTLT) Target Price at $52.46

Catalent, Inc. (NYSE:CTLT) has been given an average rating of “Hold” by the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $52.46.

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, February 20th. StockNews.com assumed coverage on shares of Catalent in a research report on Saturday. They set a “sell” rating for the company. UBS Group reaffirmed a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays boosted their price objective on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th.

Catalent Trading Up 0.2 %

Catalent stock opened at $55.92 on Friday. Catalent has a one year low of $31.45 and a one year high of $60.20. The company’s fifty day moving average price is $56.68 and its two-hundred day moving average price is $48.66. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a market capitalization of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.02 and a beta of 1.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $0.62 EPS. The business’s revenue was down 10.2% on a year-over-year basis. On average, analysts forecast that Catalent will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Catalent

A number of institutional investors and hedge funds have recently modified their holdings of the company. Lindbrook Capital LLC boosted its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Catalent by 450.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 59,452 shares of the company’s stock valued at $3,356,000 after acquiring an additional 48,655 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Catalent by 90.0% in the first quarter. Assenagon Asset Management S.A. now owns 835,029 shares of the company’s stock valued at $47,137,000 after acquiring an additional 395,629 shares during the period. IFM Investors Pty Ltd raised its position in Catalent by 10.5% in the first quarter. IFM Investors Pty Ltd now owns 35,543 shares of the company’s stock worth $2,006,000 after purchasing an additional 3,372 shares in the last quarter. Finally, Norden Group LLC bought a new position in Catalent during the first quarter worth about $1,222,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.